Congressional Medicare advisers on Thursday (Oct. 7) began discussing policies for controlling drug prices, primarily in Part B, that include setting value-based payments for first-in-class drugs, setting prices for drugs with alternative treatments using reference pricing and changing the provider reimbursement formula in Part B for administering drugs. The Medicare Payment Advisory Commission (MedPAC) also considered referencing international prices for a one-time rebasing of prices in Part B, but that policy got less attention than domestic reference pricing schemes, such...